BioCentury
ARTICLE | Company News

UTHR soars on patent win

August 30, 2014 12:23 AM UTC

United Therapeutics Corp. (NASDAQ:UTHR) gained $26.14 (29%) to $117.83 on Friday after the U.S. District Court for the District of New Jersey ruled that Sandoz's ANDA for generic intravenous treprostinil will infringe United Therapeutics' U.S. Patent No. 6,765,117.

The '117 patent expires on October 24, 2017. It covers multiple forms of treprostinil, a synthetic long-acting stable prostacyclin analog available from United Therapeutics as Remodulin in both subcutaneous injection and intravenous forms. United Therapeutics also sells an inhalable version as Tyvaso and an oral form as Orenitram. ...